New Dupixent® (dupilumab) analyses reinforce long-term safety and efficacy profile in patients with atopic dermatitis as young as 6 years streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Share this article
TARRYTOWN, N.Y. and PARIS, March 4, 2021 /PRNewswire/
Submission supported by data demonstrating Dupixent significantly reduced severe asthma attacks and is the only biologic to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial
Dupixent has the potential to be a best-in-class treatment option in this younger population of children aged 6 to 11
Acceptance represents another milestone in the development of Dupixent in addressing diseases driven by type 2 inflammation
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for Dupixent
FDA Accepts Dupixent® (dupilumab) for Review in Children with Moderate-to-severe Asthma prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
New Dupixent® (dupilumab) Data Showcasing Improvements Across Four Type 2 Inflammatory Diseases to be Presented at 2021 AAAAI Annual Meeting
News provided by
Share this article
TARRYTOWN, N.Y. and PARIS, Feb. 1, 2021 /PRNewswire/
Improvements were noted across key disease measures in certain patients with asthma, atopic dermatitis, eosinophilic esophagitis and chronic rhinosinusitis with nasal polyposis
New analyses build on a robust body of evidence reinforcing the role of Dupixent in certain diseases driven by type 2 inflammation
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced new data further examining Dupixent
® (dupilumab) in diseases driven by type 2 inflammation including atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP) and eosinophilic esophagitis. These data will be presented at the American Academy of Allergy, Asthma and Immunology (AAAAI) Virtual Annual Meeting, taking place from February 26 to March 1.